Liver Diseases  >>  Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Heplisav-B (hepatitis B vaccine (recombinant), adjuvanted) / Dynavax
NCT00426712: Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients

Completed
1
42
US
1018 ISS immunostimulatory oligonucleotide with HBV surface antigen, HEPLISAV™, Hepatitis B Vaccine (Recombinant), ENGERIX-B®
Dynavax Technologies Corporation
Hepatitis B
03/08
03/08
NCT01999699: A Study of the Immune Response to Heplisav in Healthy Older Adults

Completed
1
25
US
HEPLISAV
Dynavax Technologies Corporation, Baylor Research Institute
Hepatitis B
02/15
03/15

Download Options